Company Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
The company’s product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Its product pipeline consists of AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth.
The company has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide.
Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Mar 20, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 181 |
| CEO | John Butler |
Contact Details
Address: 245 First Street, Suite 1400 Cambridge, Massachusetts 02142 United States | |
| Phone | 617 871 2098 |
| Website | akebia.com |
Stock Details
| Ticker Symbol | AKBA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001517022 |
| CUSIP Number | 00972D105 |
| ISIN Number | US00972D1054 |
| Employer ID | 20-8756903 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John P. Butler MBA | Chief Executive Officer, President and Director |
| Dr. Steven Keith Burke M.D. | Senior Vice President of Research and Development and Chief Medical Officer |
| Erik John Ostrowski M.B.A. | Senior Vice President, Chief Financial Officer and Chief Business Officer |
| Richard C. Malabre | Chief Accounting Officer |
| Kimberly Garko | Senior Vice President and Chief Technical Officer |
| Tracey Vetterick | Vice President of Portfolio Strategy and Corporate Administration |
| Mercedes Carrasco | Senior Director of Investor and Corporate Communications |
| Carolyn Rucci | Senior Vice President of Legal, General Counsel and Secretary |
| Meredith Bowman | Senior Vice President and Chief People Officer |
| Nicholas Grund | Senior Vice President and Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 424B5 | Filing |
| Mar 19, 2025 | 424B5 | Filing |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 144 | Filing |
| Mar 3, 2025 | 144 | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | 8-K | Current Report |
| Feb 3, 2025 | 144 | Filing |